Similar articles

• Antitumor activity of the monoclonal antibody-Vinca alkaloid immunoconjugate LY203725 (KS1/4-4-desacetylvinblastine-3-carboxhydrazide) in a nude mouse model of human ovarian cancer.

  Apelgren LD, Zimmerman DL, Briggs SL, Bumol TF. Apelgren LD, et al. Cancer Res. 1990 Jun 15;50(12):3540-4. Cancer Res. 1990. PMID: 2340502
• Disposition of the monoclonal antibody-vinca alkaloid conjugate KS1/4-DAVLB (LY256787) and free 4-desacetylvinblastine in tumor-bearing nude mice.

  Spearman ME, Goodwin RM, Apelgren LD, Bumol TF. Spearman ME, et al. J Pharmacol Exp Ther. 1987 May;241(2):695-703. J Pharmacol Exp Ther. 1987. PMID: 3494841
• In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates.

  Starling JJ, Maciak RS, Hinson NA, Hoskins J, Laguzza BC, Gadski RA, Strnad J, Rittmann-Grauer L, DeHerdt SV, Bumol TF, et al. Starling JJ, et al. Cancer Res. 1990 Dec 1;50(23):7634-40. Cancer Res. 1990. PMID: 1979247
• The use of anthracycline-antibody complexes for specific antitumor activity.

  Pietersz GA, Smyth MJ, Farquhar I, McKenzie C. Pietersz GA, et al. Targeted Diagn Ther. 1988;1:25-53. Targeted Diagn Ther. 1988. PMID: 2979059 Review. No abstract available.
• Monoclonal antibody-mediated targeting of alkylating agents for the treatment of cancer.

  Smyth MJ, Pietersz GA, Farquhar I, McKenzie C. Smyth MJ, et al. Targeted Diagn Ther. 1988;1:123-56. Targeted Diagn Ther. 1988. PMID: 2979055 Review. No abstract available.